Intranasal dexmedetomidine sedation in pediatric electroencephalography: dose optimization, safety, and EEG characteristics.
Yun Hee-Jeong HJ, Youn Ina I, Lee Na Yeon NY, Kook Minhee M et al.
To evaluate the efficacy and safety of intranasal dexmedetomidine (DEX) for sedation during pediatric EEG and to explore whether EEG spectral characteristics under DEX differ from those under chloral hydrate. In this retrospective cohort study, 224 children (0-18 years) who underwent EEG under intranasal DEX sedation at a single tertiary center (January 2024-April 2025) were analyzed. Patients were stratified into weight-based dosing (Group 1, <50 kg; median 2 μg/kg) and fixed dosing (Group 2, ≥50 kg; median 100 μg). Sedation success, onset time, total sedation time, and adverse events were assessed. In a within-subject subgroup of 11 patients with a prior chloral hydrate EEG, relative power spectral density (rPSD) in the delta, theta, alpha, and beta bands during N1 and N2 sleep was compared using patient-level paired analyses, with mean paired differences, 95% confidence intervals (CIs), and correction for multiple comparisons. Initial sedation success was 94.6% in Group 1 and 94.7% in Group 2; all patients achieved adequate sedation after rescue dosing. Median onset time was 10 minutes in both groups. Adverse events were mild and self-limited (3.2% and 2.6%). No statistically significant differences in rPSD between DEX and chloral hydrate were detected in either sleep stage after correction for multiple comparisons; however, the CIs were wide, and equivalence could not be established. Interictal epileptiform discharges were visually unchanged. Intranasal DEX is an effective, well-tolerated sedative for pediatric EEG, and a weight-stratified dosing strategy appears practical. In a small paired subgroup, no significant spectral differences from chloral hydrate were detected; these preliminary quantitative findings warrant confirmation in larger studies.